Trial Profile
Phase I/II Open Label Dose Escalation and Dose Expansion Study of Intravenous Infusion of W0101, an Antibody-drug Conjugate, in Patients With Advanced or Metastatic Solid Tumors. International, Multicenter, Open Label Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 01 Aug 2023
Price :
$35
*
At a glance
- Drugs W 0101 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms Ulysse
- Sponsors Pierre Fabre
- 31 Jul 2023 This trial has been discontinued in Spain (Date of the global end of the trial: 5 July 2022).
- 19 Dec 2022 Status changed from recruiting to active, no longer recruiting.
- 11 Aug 2021 Planned End Date changed from 30 Sep 2023 to 30 Dec 2024.